Clinical trialNCT06129864RecruitingPhase 3Interventional

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

SponsorAstraZenecaEnrollment1,145Locally Advanced Head and Neck Squamous Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lisa Licitra, MD
Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan Milan, Italy
Study Chair
clinicaltrials.gov ↗
Robert Haddad, MD
Dana Farber Cancer Institute Massachusetts, USA
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

306 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Research Site
Graz, Austria
Recruiting
Research Site
Innsbruck, Austria
Recruiting
Research Site
Linz, Austria
Recruiting
Research Site
Salzburg, Austria
Recruiting
Research Site
Vienna, Austria
Recruiting

Belgium

Research Site
Charleroi, Belgium
Recruiting
Research Site
Edegem, Belgium
Recruiting
Research Site
Jette, Belgium
Recruiting
Research Site
La Louvière, Belgium
Recruiting
Research Site
Namur, Belgium
Recruiting

Brazil

Research Site
Barretos, Brazil
Recruiting
Research Site
Florianópolis, Brazil
Recruiting
Research Site
Fortaleza, Brazil
Recruiting
Research Site
Ijuí, Brazil
Recruiting
Research Site
Ipatinga, Brazil
Recruiting
Research Site
Londrina, Brazil
Recruiting
Research Site
Natal, Brazil
Recruiting
Research Site
Porto Alegre, Brazil
Recruiting
Research Site
Ribeirão Preto, Brazil
Suspended
Research Site
Rio de Janeiro, Brazil
Suspended
Research Site
São Paulo, Brazil
Recruiting
Research Site
São Paulo, Brazil
Recruiting
Research Site
Teresina, Brazil
Recruiting

Canada

Research Site
Calgary, Alberta, Canada
Recruiting
Research Site
Edmonton, Alberta, Canada
Recruiting
Research Site
Kelowna, British Columbia, Canada
Recruiting
Research Site
Kingston, Ontario, Canada
Recruiting
Research Site
London, Ontario, Canada
Recruiting
Research Site
Toronto, Ontario, Canada
Recruiting
Research Site
Chicoutimi, Quebec, Canada
Not, yet, recruiting
Research Site
Montreal, Quebec, Canada
Completed
Research Site
Montreal, Quebec, Canada
Terminated
Research Site
Montreal, Quebec, Canada
Recruiting
Research Site
Regina, Canada
Withdrawn

China

Research Site
Beijing, China
Recruiting
Research Site
Beijing, China
Recruiting
Research Site
Bengbu, China
Recruiting
Research Site
Changchun, China
Withdrawn
Research Site
Changsha, China
Recruiting
Research Site
Changsha, China
Recruiting

266 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 14 Dec 2023
Primary completion: 17 Apr 2030
Completion: 28 Feb 2031
Last update posted: 24 Jun 2026
Registered enrollment: 1,145
Registry id: NCT06129864

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.